MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next.
"Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
